Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study - PubMed
5 hours ago
- #CAR T cell therapy
- #Immunotherapy
- #Hepatocellular carcinoma
- JWATM204 is a novel GPC3-targeted CAR T cell therapy for advanced hepatocellular carcinoma (HCC).
- Phase I study evaluated safety and tolerability in GPC3-positive HCC patients, using three dose levels.
- Only mild to moderate cytokine release syndrome (CRS) observed, with no dose-limiting toxicities or neurotoxicity.
- Disease control rate was 33.3%, with two patients achieving stable disease and four experiencing progressive disease.
- Median overall survival was 5.05 months, with 6-month and 1-year survival rates both at 33.3%.
- Higher natural killer (NK) cell proportions in stable disease patients suggest a potential biomarker for response.
- RNA sequencing indicated upregulated CRP and CYP2E1 in progressive disease patients, linking inflammation to treatment response.
- Study concluded JWATM204 has a favorable safety profile and preliminary anti-tumor activity in advanced HCC.